RU2362569C2 - Твердая дозированная форма симетикона для перорального применения - Google Patents

Твердая дозированная форма симетикона для перорального применения Download PDF

Info

Publication number
RU2362569C2
RU2362569C2 RU2002125821/15A RU2002125821A RU2362569C2 RU 2362569 C2 RU2362569 C2 RU 2362569C2 RU 2002125821/15 A RU2002125821/15 A RU 2002125821/15A RU 2002125821 A RU2002125821 A RU 2002125821A RU 2362569 C2 RU2362569 C2 RU 2362569C2
Authority
RU
Russia
Prior art keywords
weight
simethicone
solid dosage
dosage form
microcrystalline cellulose
Prior art date
Application number
RU2002125821/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002125821A (ru
Inventor
Кристофер Э. ШИМЧАК (US)
Кристофер Э. ШИМЧАК
Джеймс Т. УОЛТЕР (US)
Джеймс Т. УОЛТЕР
Original Assignee
МакНЕЙЛ-ППС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МакНЕЙЛ-ППС, ИНК. filed Critical МакНЕЙЛ-ППС, ИНК.
Publication of RU2002125821A publication Critical patent/RU2002125821A/ru
Application granted granted Critical
Publication of RU2362569C2 publication Critical patent/RU2362569C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2002125821/15A 2001-09-28 2002-09-27 Твердая дозированная форма симетикона для перорального применения RU2362569C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form
US09/966,441 2001-09-28

Publications (2)

Publication Number Publication Date
RU2002125821A RU2002125821A (ru) 2004-03-27
RU2362569C2 true RU2362569C2 (ru) 2009-07-27

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002125821/15A RU2362569C2 (ru) 2001-09-28 2002-09-27 Твердая дозированная форма симетикона для перорального применения

Country Status (18)

Country Link
US (3) US7101573B2 (OSRAM)
EP (1) EP1297825B1 (OSRAM)
AR (1) AR036700A1 (OSRAM)
AT (1) ATE296619T1 (OSRAM)
AU (1) AU2002301259C1 (OSRAM)
BR (1) BR0204001A (OSRAM)
CA (1) CA2405190C (OSRAM)
CO (1) CO5390073A1 (OSRAM)
DE (1) DE60204403T2 (OSRAM)
DK (1) DK1297825T3 (OSRAM)
ES (1) ES2243664T3 (OSRAM)
HU (1) HUP0203176A2 (OSRAM)
MX (1) MXPA02009570A (OSRAM)
NZ (1) NZ521657A (OSRAM)
PL (1) PL204141B1 (OSRAM)
PT (1) PT1297825E (OSRAM)
RU (1) RU2362569C2 (OSRAM)
ZA (1) ZA200207755B (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2617510C2 (ru) * 2011-09-08 2017-04-25 Новартис Аг Фармацевтические композиции, содержащие ингибитор ароматазы
RU2630606C2 (ru) * 2011-12-05 2017-09-11 Альтергон С.А. Устойчивые составы антитромбоцитарных средств, омега-3 жирных кислот и амилозы в мягких желатиновых капсулах
RU2640920C2 (ru) * 2011-10-27 2018-01-12 Саликс Фармасьютикалз, ИНК. Электролитные слабительные средства

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) * 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
EP1509204A4 (en) * 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
UA86802C2 (ru) * 2004-04-13 2009-05-25 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
EP1862184A4 (en) * 2005-03-24 2012-12-19 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
WO2008064192A2 (en) 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Modified release analgesic suspensions
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA3050530A1 (en) 2009-01-06 2010-07-15 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
CN103619348B (zh) 2011-04-21 2016-10-26 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
WO2013095111A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US20180311201A1 (en) 2015-06-12 2018-11-01 Santa Farma ?Laç Sanay? A. ?. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
MX385008B (es) * 2016-12-14 2025-03-14 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
KR102648960B1 (ko) 2017-09-29 2024-03-20 존슨 앤드 존슨 컨수머 인코포레이티드 고체 시메티콘 입자 및 이의 투여 형태
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline
CN116159032A (zh) * 2023-03-31 2023-05-26 成都恒瑞制药有限公司 盐酸西替利嗪片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5073384A (en) 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
NZ235876A (en) 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
HU215958B (hu) * 1992-04-30 1999-03-29 Schering Corp. Eljárás stabil, hidratált, száraz ceftibuten porkészítmény előállítására perorális szuszpenziókhoz
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
EP0725630A1 (en) * 1993-10-28 1996-08-14 The Procter & Gamble Company Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients
DE69426863T2 (de) 1993-12-15 2001-09-27 National Starch And Chemical Investment Holding Corp., Wilmington Verwendung von Öl adsorbierenden natürlichen Polymeren in kosmetischen und pharmazeutischen Anwendungen
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RU 98114678 A (МАКНЕЙЛ-ППС, ИНК.), 20.05.2000. RU 99120173 A (МАКНЕЙЛ-ППС, ИНК.), 20.07.2001. Ажгихин И.С. Технология лекарств. - М.: Медицина, 1975, с.49. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2617510C2 (ru) * 2011-09-08 2017-04-25 Новартис Аг Фармацевтические композиции, содержащие ингибитор ароматазы
RU2640920C2 (ru) * 2011-10-27 2018-01-12 Саликс Фармасьютикалз, ИНК. Электролитные слабительные средства
RU2630606C2 (ru) * 2011-12-05 2017-09-11 Альтергон С.А. Устойчивые составы антитромбоцитарных средств, омега-3 жирных кислот и амилозы в мягких желатиновых капсулах

Also Published As

Publication number Publication date
US20070196468A1 (en) 2007-08-23
US7101573B2 (en) 2006-09-05
MXPA02009570A (es) 2004-07-30
PL356358A1 (en) 2003-04-07
AU2002301259B2 (en) 2009-01-22
CA2405190C (en) 2010-11-09
BR0204001A (pt) 2003-09-16
ATE296619T1 (de) 2005-06-15
EP1297825A1 (en) 2003-04-02
US20030091624A1 (en) 2003-05-15
DE60204403D1 (de) 2005-07-07
EP1297825B1 (en) 2005-06-01
CO5390073A1 (es) 2004-04-30
NZ521657A (en) 2004-05-28
HU0203176D0 (OSRAM) 2002-11-28
AR036700A1 (es) 2004-09-29
HUP0203176A2 (hu) 2004-07-28
PL204141B1 (pl) 2009-12-31
CA2405190A1 (en) 2003-03-28
DK1297825T3 (da) 2005-09-26
PT1297825E (pt) 2005-08-31
US20100135982A1 (en) 2010-06-03
US7691409B2 (en) 2010-04-06
ZA200207755B (en) 2004-03-26
RU2002125821A (ru) 2004-03-27
ES2243664T3 (es) 2005-12-01
DE60204403T2 (de) 2006-05-04
AU2002301259C1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
RU2362569C2 (ru) Твердая дозированная форма симетикона для перорального применения
US7815937B2 (en) Quick dissolve compositions and tablets based thereon
US6753009B2 (en) Soft tablet containing high molecular weight polyethylene oxide
EP1491184B1 (en) Soft tablet containing high molecular weight cellulosics
US20120082729A1 (en) Quick dissolve compositions and tablets based thereon
US7201922B2 (en) Orodispersible solid pharmaceutical form
CN1394598A (zh) 具有脆性包衣和软核的剂型
US20040265373A1 (en) Soft tablet containing high molecular weight cellulosics
JP4601271B2 (ja) 圧縮成形製剤およびその製造方法
JP2002528042A (ja) 改善された放出特性を有する投与形態
US20030228370A1 (en) Orodispersible solid pharmaceutical form
MX2008004381A (en) Oral composition containing a salivation inducing agent

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070329

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20080320

MM4A The patent is invalid due to non-payment of fees

Effective date: 20190928